NCT04622761 (CHROME) is a Phase 2 clinical trial of Cabazitaxel in Prostate Cancer, sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust.

Who is sponsoring NCT04622761?

NCT04622761 is sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust.

What drugs are being tested in NCT04622761?

Interventions in NCT04622761: Cabazitaxel.

What condition does NCT04622761 study?

NCT04622761 studies Prostate Cancer.

Is NCT04622761 still recruiting?

NCT04622761 is currently not yet recruiting. Last updated 5 January 2021.

Last reviewed 2021-01-05 · How we verify

NCT04622761: CHROME

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome

Not yet recruiting Phase 2 Last updated 5 January 2021

What this trial tests

Phase 2 trial testing Cabazitaxel in Prostate Cancer in 120 participants. Not yet recruiting.

Timeline

15 January 2021

Primary endpoint
2 November 2025

2 May 2026

Quick facts

Lead sponsor	The Clatterbridge Cancer Centre NHS Foundation Trust
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	15 January 2021
Primary completion	2 November 2025
Estimated completion	2 May 2026

Drugs / interventions tested

Cabazitaxel (cabazitaxel) — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust

Who can join

18 and older, any sex, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is evaluating the efficacy of cabazitaxel and hormonal treatment as neoadjuvant treatment for patients with clinically operable disease suitable for surgery, and a high risk of relapse after surgery

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cabazitaxel

Trials testing the same drug.

NCT07213674 — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic · Phase 3 · recruiting
NCT06632977 — Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial · Phase 2 · recruiting
NCT06691984 — Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressiv · Phase 3 · recruiting
NCT06353386 — Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Particip · Phase 1, PHASE2 · recruiting
NCT06085729 — Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Var · Phase 1, PHASE2 · recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other The Clatterbridge Cancer Centre NHS Foundation Trust trials

Trials by the same sponsor.

NCT07342335 — Breaking Barriers to Research Access · recruiting
NCT07335120 — A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma · recruiting
NCT04603105 — CCP Cancer UK Companion Study · active not recruiting
NCT03721757 — CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer · Phase 2 · completed
NCT04268888 — Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC · Phase 2, PHASE3 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04622761 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Clatterbridge Cancer Centre NHS Foundation Trust
Last refreshed: 5 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04622761.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing